Clinical trial results:
A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF)

Summary

EudraCT number	2010-024252-29
Trial protocol	FI DE PT GR NL ES
Global end of trial date	15 October 2013

Results information

Result version number	v1 (current)
This version publication date	20 June 2016
First version publication date	01 August 2015

Trial information

Trial identification

Sponsor protocol code	1199.34

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01335477
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Boehringer Ingelheim
Sponsor organisation address	Binger Strasse 173 , Ingelheim am Rhein , Germany,
Public contact	QRPE Processes and Systems Coordination , Boehringer Ingelheim Pharma GmbH & Co. KG , +1 800243 0127, clintriage.rdg@boehringer-ingelheim.com
Scientific contact	QRPE Processes and Systems Coordination, Boehringer Ingelheim Pharma GmbH & Co. KG , +1 800243 0127, clintriage.rdg@boehringer-ingelheim.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 November 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 September 2013
Global end of trial reached?	Yes
Global end of trial date	15 October 2013
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate a reduction of lung function decline, as measured by a change of the yearly rate of decline of forced vital capacity (FVC).

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all patients as required.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 May 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	7 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 20
Country: Number of subjects enrolled	Chile: 11
Country: Number of subjects enrolled	China: 84
Country: Number of subjects enrolled	Finland: 21
Country: Number of subjects enrolled	France: 76
Country: Number of subjects enrolled	Germany: 52
Country: Number of subjects enrolled	Greece: 28
Country: Number of subjects enrolled	India: 35
Country: Number of subjects enrolled	Japan: 83
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 97
Country: Number of subjects enrolled	Mexico: 7
Country: Number of subjects enrolled	Netherlands: 23
Country: Number of subjects enrolled	Portugal: 28
Country: Number of subjects enrolled	Russian Federation: 4
Country: Number of subjects enrolled	Spain: 28
Country: Number of subjects enrolled	Turkey: 55
Country: Number of subjects enrolled	United States: 142
Worldwide total number of subjects	794
EEA total number of subjects	256

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	314
From 65 to 84 years	475
85 years and over	5

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All subjects were screened for eligibility to participate in the trial. Subjects attended one specialist site which would then ensure that they (the subjects) met all inclusion/exclusion criteria. Subjects were not to be randomised to trial treatment if any one of the specific entry criteria were violated.

Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Oral administration of placebo matching nintedanib soft gelatine capsules.
One patient was randomised to the placebo arm, however this patient was not treated.
Consequently, number of subject that started is 220 but only 219 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

Oral administration of placebo matching nintedanib soft gelatine capsules.
twice daily (bid)

Arm title	Nintedanib 150mg

Arm description:

Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.
Two patients were randomised to the placebo arm, however those two patients were not treated.
Consequently, number of subject that started is 331 but only 329 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Arm type	Experimental
Investigational medicinal product name	Nintedanib 150mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

twice daily (bid)

Number of subjects in period 1[1]	Placebo	Nintedanib 150mg
Started	219	329
Completed	179	272
Not completed	40	57
Consent withdrawn, not due to AE	7	9
Adverse event, serious fatal	23	24
Non compliant with protocol	-	2
Adverse event, non-fatal	7	18
Reason other than those stated above	2	2
Lost to follow-up	1	2

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Baseline characteristics are based on patients who were randomised after successfully completing the screening period and received at least one of the trial medication.

Baseline characteristics

Reporting groups	
Reporting group title	Placebo

Reporting group description:

Oral administration of placebo matching nintedanib soft gelatine capsules.
One patient was randomised to the placebo arm, however this patient was not treated. Consequently, number of subject that started is 220 but only 219 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Reporting group title	Nintedanib 150mg

Reporting group description:

Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.
Two patients were randomised to the placebo arm, however those two patients were not treated. Consequently, number of subject that started is 331 but only 329 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Reporting group values	Placebo	Nintedanib 150mg	Total
Number of subjects	219	329	548
Age categorical Units: Subjects			

Age continuous			
Treated set (TS): The TS consisted of randomised patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment			
Units: years			
arithmetic mean	67.1	66.4	
standard deviation	± 7.5	± 7.9	-
Gender categorical			
Treated set (TS): The TS consisted of randomised patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment			
Units: Subjects			
Female	48	73	121
Male	171	256	427

End points

End points reporting groups

Reporting group title	Placebo

Reporting group description:

Oral administration of placebo matching nintedanib soft gelatine capsules.
One patient was randomised to the placebo arm, however this patient was not treated.
Consequently, number of subject that started is 220 but only 219 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Reporting group title	Nintedanib 150mg

Reporting group description:

Oral administration of soft gelatine capsules of nintedanib 150mg twice daily (bid).
Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.
Two patients were randomised to the placebo arm, however those two patients were not treated.
Consequently, number of subject that started is 331 but only 329 reported to ensure consistent reporting with baseline characteristics that includes only treated patients.

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.

End point title	Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.

End point description:

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

End point type	Primary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[1]	329[2]		
Units: mL/year				
arithmetic mean (standard error)	-207.32 (± 19.309)	-113.59 (± 15.726)		

Notes:

[1] - Treated Set (Only patients with observed cases (OC) values were analysed)

[2] - Treated Set (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Random coefficient regression with fixed effects for treatment, gender, age, height and random effect of patient specific intercept and time.
A hierarchical procedure was used in order to demonstrate the superiority of nintedanib over placebo for the primary and two key secondary endpoints.
The consecutive steps of the hierarchy were only considered if the previous step was significant at the one-sided 2.5% level and the results were in favour of nintedanib.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[3]
P-value	= 0.0002
Method	Random coefficient regression
Parameter estimate	Mean difference (final values)
Point estimate	93.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	44.78
upper limit	142.68
Variability estimate	Standard error of the mean
Dispersion value	24.907

Notes:

[3] - The Roger-Kenward approximation was used to estimate denominators degrees of freedom.
Within-patient errors are modelled by an Unstructured variance-covariance matrix.
Inter-individual variability is modelled by a Variance-components variance-covariance matrix.
Nintedanib 150 mg bid versus Placebo.

Secondary: Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

End point title	Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

End point description:

This is a key secondary endpoint.
SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213[4]	320[5]		
Units: points on a scale				
arithmetic mean (standard error)	5.48 (± 0.891)	2.8 (± 0.73)		

Notes:

[4] - TS (Only patients with observed cases (OC) values were analysed)

[5] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Total score, baseline SGRQ Total score-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority[6]
P-value	= 0.0197
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-2.69
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.95
upper limit	-0.43
Variability estimate	Standard error of the mean
Dispersion value	1.151

Notes:

[6] - Nintedanib 150 mg bid versus Placebo.
Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

End point title	Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and
represented as a key secondary endpoint.
An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
- Unexplained worsening or development of dyspnoea within 30 days
- New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit
- Exclusion of infection as per routine clinical practice and microbiological studies
- Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks (up to randomisation + 372 days), based on all investigator-

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[7]	329[8]		
Units: percentage of participants				
number (not applicable)				
Failure	9.6	3.6		
Censored	90.4	96.4		

Notes:

[7] - Treated Set (Only patients with observed cases (OC) values were analysed)

[8] - Treated Set (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard Ratio is based on a Cox's regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[9]
P-value	= 0.005
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	0.77

Notes:

[9] - Nintedanib 150 mg bid versus Placebo.

Secondary: Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 weeks

End point title	Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 weeks

End point description:

Means provided are the adjusted means. Adjusted mean is based on all analysed patients in the model (not only patients with a change from baseline to week 52).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217[10]	327[11]		
Units: mL				
arithmetic mean (standard error)	-205.03 (± 16.629)	-95.26 (± 14.2)		

Notes:

[10] - TS (Only patients with observed cases (OC) values were analysed)

[11] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC -by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	544
Analysis specification	Pre-specified
Analysis type	superiority[12]
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	109.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	70.92
upper limit	148.62
Variability estimate	Standard error of the mean
Dispersion value	19.808

Notes:

[12] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

End point title	Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

End point description:

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217[13]	327[14]		
Units: %predicted				
arithmetic mean (standard error)	-6.15 (± 0.505)	-3.09 (± 0.433)		

Notes:

[13] - TS (Only patients with observed cases (OC) values were analysed)

[14] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	544
Analysis specification	Pre-specified

Analysis type	superiority[15]
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	3.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.87
upper limit	4.25
Variability estimate	Standard error of the mean
Dispersion value	0.607

Notes:

[15] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

End point title	Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

End point description:

Absolute categorical change of FVC (% predicted) by categories at 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within ≤5%).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	269		
Units: percentage of participants				
number (not applicable)				
Decrease > 5%	52.2	34.9		
Change within ≤ 5%	45	50.2		
Increase > 5%	2.8	14.9		

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

End point title	Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

End point description:

Absolute categorical change of FVC (% predicted) by categories at 52 weeks - 10% threshold (decrease by > 10%, increase by >10%, and change within ≤10%)

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	269		
Units: percentage of participants				
number (not applicable)				
Decrease > 10%	22.2	14.9		
Change within ≤ 10%	77.2	80.7		
Increase > 10%	0.6	4.5		

Statistical analyses

No statistical analyses for this end point

Secondary: FVC Responders Using 10% Threshold at 52 Weeks

End point title	FVC Responders Using 10% Threshold at 52 Weeks

End point description:

FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[16]	329[17]		
Units: percentage of participants				
number (confidence interval 95%)	63.93 (57.38 to 70)	69.6 (64.43 to 74.33)		

Notes:

[16] - TS (Only patients with observed cases (OC) values were analysed)

[17] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted

Comparison groups	Placebo v Nintedanib 150mg

Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[18]
P-value	= 0.1833
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.286
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.89
upper limit	1.86

Notes:

[18] - Nintedanib 150 mg bid versus Placebo

Secondary: Proportion of FVC Responders Using 5% Threshold at 52 Weeks

End point title	Proportion of FVC Responders Using 5% Threshold at 52 Weeks

End point description:

Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[19]	329[20]		
Units: percentage of participants				
number (confidence interval 95%)	39.27 (33.04 to 45.87)	53.19 (47.79 to 58.52)		

Notes:

[19] - TS (Only patients with observed cases (OC) values were analysed)

[20] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Logistic regression with terms treatment, age, gender, height and baseline FVC % predicted

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[21]
P-value	= 0.0011
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.794
Confidence interval	

level	95 %
sides	2-sided
lower limit	1.26
upper limit	2.55

Notes:

[21] - Nintedanib 150 mg bid versus Placebo

Secondary: Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

Proportion of SGRQ Responders at 52 Weeks. Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks.

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[22]	329[23]		
Units: percentage of participants				
number (confidence interval 95%)	16.89 (12.51 to 22.42)	25.23 (20.84 to 30.19)		

Notes:

[22] - TS (Only patients with observed cases (OC) values were analysed)

[23] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Logistic regression with terms treatment, baseline SGRQ total score

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[24]
P-value	= 0.0218
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.664
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.08
upper limit	2.57

Notes:

[24] - Nintedanib 150 mg bid versus Placebo

Secondary: Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point title	Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point description:

SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and
severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	214[25]	323[26]		
Units: points on a scale				
arithmetic mean (standard error)	3.43 (± 1.297)	2.03 (± 1.061)		

Notes:

[25] - TS (Only patients with observed cases (OC) values were analysed)

[26] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Symptoms component, baseline SGRQ Symptoms component-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	537
Analysis specification	Pre-specified
Analysis type	superiority[27]
P-value	= 0.4019
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.69
upper limit	1.88
Variability estimate	Standard error of the mean
Dispersion value	1.675

Notes:

[27] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point title	Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point description:

SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.

Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	214[28]	322[29]		
Units: points on a scale				
arithmetic mean (standard error)	7.2 (± 1.052)	3.89 (± 0.863)		

Notes:

[28] - TS (Only patients with observed cases (OC) values were analysed)

[29] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ Activities component, baseline SGRQ Activities component-by-visit and random effect for patient

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	536
Analysis specification	Pre-specified
Analysis type	superiority[30]
P-value	= 0.0152
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-3.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.97
upper limit	-0.64
Variability estimate	Standard error of the mean
Dispersion value	1.36

Notes:

[30] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point title	Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point description:

SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological
disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better
impact-related quality of life.

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	215[31]	320[32]		
Units: points on a scale				
arithmetic mean (standard error)	5.93 (± 1.036)	2.85 (± 0.852)		

Notes:

[31] - TS (Only patients with observed cases (OC) values were analysed)

[32] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ impact component, baseline SGRQ impact component-by-visit and random effect for patient

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	535
Analysis specification	Pre-specified
Analysis type	superiority[33]
P-value	= 0.022
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-3.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.71
upper limit	-0.45
Variability estimate	Standard error of the mean
Dispersion value	1.342

Notes:

[33] - Nintedanib 150 mg bid versus Placebo.

Within-patient error are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point title	Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

End point description:

SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and
Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213[34]	320[35]		
Units: points on a scale				
arithmetic mean (standard error)	5.84 (± 0.921)	2.72 (± 0.757)		

Notes:

[34] - TS (Only patients with observed cases (OC) values were analysed)

[35] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SGRQ-I Total score, baseline SGRQ-I Total score-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	533
Analysis specification	Pre-specified
Analysis type	superiority[36]
P-value	= 0.0089
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-3.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.46
upper limit	-0.79
Variability estimate	Standard error of the mean
Dispersion value	1.192

Notes:

[36] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	204[37]	302[38]		
Units: points on a scale				
arithmetic mean (standard error)	9.07 (± 1.3)	6.69 (± 1.073)		

Notes:

[37] - TS (Only patients with observed cases (OC) values were analysed)

[38] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline SOBQ score, baseline SOBQ score-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	506
Analysis specification	Pre-specified
Analysis type	superiority[39]
P-value	= 0.1587
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-2.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.68
upper limit	0.93
Variability estimate	Standard error of the mean
Dispersion value	1.685

Notes:

[39] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and
their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores
indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	215[40]	323[41]		
Units: points on a scale				
arithmetic mean (standard error)	-2.38 (± 1.325)	-0.33 (± 1.087)		

Notes:

[40] - TS (Only patients with observed cases (OC) values were analysed)

[41] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment,
visit, treatment-by-visit, baseline CASA-Q Cough symptoms score, baseline CASAQ
Cough symptoms score-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	538
Analysis specification	Pre-specified
Analysis type	superiority[42]
P-value	= 0.2326
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	2.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.31
upper limit	5.41

Variability estimate	Standard error of the mean
Dispersion value	1.713

Notes:

[42] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	215[43]	322[44]		
Units: points on a scale				
arithmetic mean (standard error)	-4.39 (± 1.209)	-2.58 (± 0.991)		

Notes:

[43] - Treated set

[44] - Treated set

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, treatment-by-visit, baseline CASA-Q Cough impact score, baseline CASA-Q Cough impact score-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	537
Analysis specification	Pre-specified
Analysis type	superiority[45]
P-value	= 0.2475
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	1.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.26

upper limit	4.88
Variability estimate	Standard error of the mean
Dispersion value	1.564

Notes:

[45] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

Proportion of Patient's Global Impression of Change (PGI-C) responders at 52 weeks. Responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[46]	329[47]		
Units: percentage of participants				
number (confidence interval 95%)	53.88 (47.27 to 60.36)	61.7 (56.34 to 66.79)		

Notes:

[46] - TS (Only patients with observed cases (OC) values were analysed)

[47] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Logistic regression with term treatment

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[48]
P-value	= 0.069
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.379
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.98
upper limit	1.95

Notes:

[48] - Nintedanib 150 mg bid versus Placebo

Secondary: Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks: Patient Reported Outcomes (PROs)

End point title	Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks: Patient Reported Outcomes (PROs)

End point description:

The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.

End point type	Secondary

End point timeframe:

baseline, 12 weeks, 24 weeks and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[49]	329[50]		
Units: points on a scale				
arithmetic mean (standard deviation)				
12 weeks (N=207, 306)	-1.48 (± 15.6)	-0.57 (± 16.97)		
24 weeks (N=204, 297)	-4.86 (± 16.94)	-1.1 (± 16.81)		
52 weeks (N=178, 265)	-5.6 (± 17.67)	-2.52 (± 16.95)		

Notes:

[49] - TS (Only patients with observed cases (OC) values were analysed)

[50] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Death Over 52 Weeks

End point title	Time to Death Over 52 Weeks

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (up to 372 days after randomisation).

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[51]	329[52]		
Units: percentage of participants				
number (not applicable)				
Failure	9.1	6.7		
Censored	90.9	93.3		

Notes:

[51] - TS (Only patients with observed cases (OC) values were analysed)

[52] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard ratio is based on a Cox´s regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[53]
P-value	= 0.2995
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.35

Notes:

[53] - Nintedanib 150 mg bid versus Placebo

Secondary: Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

End point title	Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to
respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (up to 372 days after randomisation).

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[54]	329[55]		
Units: percentage of participants				
number (not applicable)				
Failure	5	4.3		
Censored	95	95.7		

Notes:

[54] - TS (Only patients with observed cases (OC) values were analysed)

[55] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[56]
P-value	= 0.6654
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.9

Notes:

[56] - Nintedanib 150 mg bid versus Placebo

Secondary: Time to On-treatment Death

End point title	Time to On-treatment Death

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial
medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment (up to 28 days after last treatment intake).

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[57]	329[58]		
Units: percentage of participants				
number (not applicable)				
Failure	7.8	4.9		
Censored	92.2	95.1		

Notes:

[57] - TS (Only patients with observed cases (OC) values were analysed)

[58] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard ratio is based on a Cox´s regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[59]
P-value	= 0.2209
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	1.35

Notes:

[59] - Nintedanib 150 mg bid versus Placebo

Secondary: Time to Death or Lung Transplant Over 52 Weeks

End point title	Time to Death or Lung Transplant Over 52 Weeks

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died or had lung transplant over 52 weeks (up to 372 days after randomisation).

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[60]	329[61]		
Units: percentage of participants				
number (not applicable)				
Failure	10	6.7		
Censored	90	93.3		

Notes:

[60] - TS (Only patients with observed cases (OC) values were analysed)

[61] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[62]
P-value	= 0.1664
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.21

Notes:

[62] - Nintedanib 150 mg bid versus Placebo

Secondary: Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

End point title	Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

End point description:

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (up to 372 days after randomisation).

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[63]	329[64]		
Units: percentage of participants				
number (not applicable)				
Failure	23.7	19.5		
Censored	76.3	80.5		

Notes:

[63] - TS (Only patients with observed cases (OC) values were analysed)

[64] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Hazard ratio is based on Cox´s regression model with terms for treatment, gender, age and height.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[65]
P-value	= 0.2123
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.16

Notes:

[65] - Nintedanib 150 mg bid versus Placebo

Secondary: Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

End point title	Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

End point description:

Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	212[66]	320[67]		
Units: percent of oxygen saturation				
arithmetic mean (standard error)	-0.66 (± 0.174)	-0.39 (± 0.149)		

Notes:

[66] - TS (Only patients with observed cases (OC) values were analysed)

[67] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline SpO2, baseline SpO2-by-visit and random effect for patient

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	532
Analysis specification	Pre-specified
Analysis type	superiority[68]
P-value	= 0.2032
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.69
Variability estimate	Standard error of the mean
Dispersion value	0.213

Notes:

[68] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

End point title	Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

End point description:

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

End point type	Secondary

End point timeframe:

baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	202[69]	302[70]		
Units: mmol/min/kPa				
arithmetic mean (standard error)	-0.4 (± 0.0843)	-0.286 (± 0.0729)		

Notes:

[69] - TS (Only patients with observed cases (OC) values were analysed)

[70] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Mixed Model for Repeated Measures with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline DLCO (HGB Corrected) [mmol/min/kPa], baseline DLCO (HGB Corrected) [mmol/min/kPa]-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	504
Analysis specification	Pre-specified
Analysis type	superiority[71]
P-value	= 0.26
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	0.113
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.084
upper limit	0.31

Notes:

[71] - Nintedanib 150 mg bid versus Placebo.

Within-patient errors are modelled by compound symmetry covariance matrix.

Secondary: Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

End point title	Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

End point description:

Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217[72]	327[73]		
Units: percent change				
arithmetic mean (standard error)	-8.14 (± 0.62)	-3.9 (± 0.528)		

Notes:

[72] - Treated Set (Only patients with observed cases (OC) values were analysed)

[73] - Treated Set (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC, baseline FVC-by visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	544
Analysis specification	Pre-specified
Analysis type	superiority[74]
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	4.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.78
upper limit	5.69
Variability estimate	Standard error of the mean
Dispersion value	0.742

Notes:

[74] - Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.

Secondary: Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

End point title	Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

End point description:

Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

End point type	Secondary

End point timeframe:

Baseline and 52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	217[75]	327[76]		
Units: percent change				
arithmetic mean (standard error)	-8.13 (± 0.614)	-3.92 (± 0.525)		

Notes:

[75] - TS (Only patients with observed cases (OC) values were analysed)

[76] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Based on Mixed Model for Repeated Measures (MMRM), with fixed effects for treatment, visit, gender, age, height, treatment-by-visit, baseline FVC [%predicted], baseline FVC [%predicted]-by-visit and random effect for patient.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	544
Analysis specification	Pre-specified
Analysis type	superiority[77]
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	4.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.76
upper limit	5.67
Variability estimate	Standard error of the mean
Dispersion value	0.743

Notes:

[77] - Nintedanib 150 mg bid versus Placebo.
Within-patient errors are modelled by compound symmetry covariance matrix.
Clinical

Secondary: Risk of an Acute IPF Exacerbation Over 52 Weeks

End point title	Risk of an Acute IPF Exacerbation Over 52 Weeks

End point description:

Incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk *100)

End point type	Secondary

End point timeframe:

52 weeks

End point values	Placebo	Nintedanib 150mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	219[78]	329[79]		
Units: Participants/Year *100				
number (not applicable)	10.2	3.9		

Notes:

[78] - TS (Only patients with observed cases (OC) values were analysed)

[79] - TS (Only patients with observed cases (OC) values were analysed)

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Risk ratio was calculated as the ratio of risk of exacerbation in both treatment groups. The log of the risk ratio was assumed to follow a normal distribution with mean 0 and variance equal to the sum of the reciprocals of the number of patients with at least one exacerbation in each treatment arm.

Comparison groups	Placebo v Nintedanib 150mg
Number of subjects included in analysis	548
Analysis specification	Pre-specified
Analysis type	superiority[80]
P-value	= 0.007
Method	Normal distribution
Parameter estimate	Risk ratio (RR)
Point estimate	0.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	0.77

Notes:

[80] - Nintedanib 150 mg bid versus Placebo.

Adverse events

Adverse events information	
Timeframe for reporting adverse events:	
From the first drug administration until 28 days after the last drug administration, up to 428 days.	
Assessment type	Systematic
Dictionary used	
Dictionary name	MedDRA
Dictionary version	16.1
Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Oral administration of Placebo matching nintedanib soft gelatine capsules	
Reporting group title	Nintedanib 150mg bid
Reporting group description:	
Oral administration of soft gelatine capsules of Nintedanib 150 mg twice daily (bid). Dose interruption and reduction to 100 mg bid dose were allowed to manage adverse events.	

Serious adverse events	Placebo	Nintedanib 150mg bid	
Total subjects affected by serious adverse events			
subjects affected / exposed	72 / 219 (32.88%)	98 / 329 (29.79%)	
number of deaths (all causes)	24	30	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm rupture			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic intramural haematoma			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to	1 / 2	0 / 0	

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Coronary angioplasty			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung transplant			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheostomy			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	

occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chloroma			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Colon cancer			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma metastatic			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
Neurofibroma			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cancer			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	2 / 219 (0.91%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Burns third degree			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to	0 / 1	0 / 0	

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	1 / 219 (0.46%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Arteriogram coronary			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest X-ray abnormal			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	1 / 219 (0.46%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	2 / 219 (0.91%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiac disorder			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 219 (0.46%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiomegaly			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cor pulmonale			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 219 (0.46%)	3 / 329 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Pericardial effusion			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular dysfunction			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute respiratory failure			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dyspnoea			
subjects affected / exposed	3 / 219 (1.37%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Haemoptysis			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	3 / 219 (1.37%)	4 / 329 (1.22%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	28 / 219 (12.79%)	22 / 329 (6.69%)	
occurrences causally related to treatment / all	1 / 32	0 / 25	
deaths causally related to treatment / all	0 / 12	0 / 11	
Pleural effusion			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumomediastinum			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 219 (0.46%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	

occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 219 (0.00%)	4 / 329 (1.22%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary hypertension			
subjects affected / exposed	3 / 219 (1.37%)	6 / 329 (1.82%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory acidosis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	5 / 219 (2.28%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Sleep apnoea syndrome			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to	0 / 1	0 / 0	

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular disorder			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoparesis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Piriformis syndrome			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	

deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orbital apex syndrome			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	

occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Constipation		
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Diarrhoea		
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)
occurrences causally related to treatment / all	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Diverticulum		
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Duodenal ulcer perforation		
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Gastric ulcer		
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)
occurrences causally related to treatment / all	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Haematochezia		
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Haemorrhoids		
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Inguinal hernia		
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1

deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-alcoholic steatohepatitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	

deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Subcutaneous emphysema			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	

occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 219 (0.00%)	2 / 329 (0.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 219 (0.00%)	6 / 329 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to	0 / 1	0 / 1	

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes simplex meningoencephalitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective aneurysm			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	

deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	2 / 219 (0.91%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mycobacterial infection			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathogen resistance			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	11 / 219 (5.02%)	18 / 329 (5.47%)	
occurrences causally related to treatment / all	0 / 14	0 / 21	
deaths causally related to treatment / all	0 / 1	0 / 5	
Pulmonary tuberculosis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	3 / 219 (1.37%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	

Sepsis			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	1 / 219 (0.46%)	0 / 329 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 219 (0.46%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 219 (0.00%)	1 / 329 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Nintedanib 150mg bid	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	193 / 219 (88.13%)	308 / 329 (93.62%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	11 / 219 (5.02%)	11 / 329 (3.34%)	
occurrences (all)	12	11	

Investigations			
Weight decreased			
subjects affected / exposed	2 / 219 (0.91%)	37 / 329 (11.25%)	
occurrences (all)	2	38	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	22 / 219 (10.05%)	25 / 329 (7.60%)	
occurrences (all)	22	25	
Cough			
subjects affected / exposed	31 / 219 (14.16%)	38 / 329 (11.55%)	
occurrences (all)	37	45	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	15 / 219 (6.85%)	13 / 329 (3.95%)	
occurrences (all)	15	13	
Nervous system disorders			
Headache			
subjects affected / exposed	7 / 219 (3.20%)	22 / 329 (6.69%)	
occurrences (all)	7	27	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	20 / 219 (9.13%)	26 / 329 (7.90%)	
occurrences (all)	21	27	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 219 (3.20%)	30 / 329 (9.12%)	
occurrences (all)	7	37	
Constipation			
subjects affected / exposed	10 / 219 (4.57%)	19 / 329 (5.78%)	
occurrences (all)	10	24	
Abdominal pain upper			
subjects affected / exposed	6 / 219 (2.74%)	18 / 329 (5.47%)	
occurrences (all)	7	18	
Diarrhoea			
subjects affected / exposed	39 / 219 (17.81%)	207 / 329 (62.92%)	
occurrences (all)	56	346	
Nausea			
subjects affected / exposed	16 / 219 (7.31%)	86 / 329 (26.14%)	

occurrences (all)	16	114	
Vomiting			
subjects affected / exposed	7 / 219 (3.20%)	34 / 329 (10.33%)	
occurrences (all)	7	49	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	11 / 219 (5.02%)	8 / 329 (2.43%)	
occurrences (all)	13	9	
Back pain			
subjects affected / exposed	13 / 219 (5.94%)	20 / 329 (6.08%)	
occurrences (all)	13	22	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	10 / 219 (4.57%)	42 / 329 (12.77%)	
occurrences (all)	10	48	
Infections and infestations			
Bronchitis			
subjects affected / exposed	17 / 219 (7.76%)	26 / 329 (7.90%)	
occurrences (all)	25	37	
Nasopharyngitis			
subjects affected / exposed	34 / 219 (15.53%)	48 / 329 (14.59%)	
occurrences (all)	44	63	
Upper respiratory tract infection			
subjects affected / exposed	24 / 219 (10.96%)	30 / 329 (9.12%)	
occurrences (all)	32	39	
Respiratory tract infection			
subjects affected / exposed	13 / 219 (5.94%)	18 / 329 (5.47%)	
occurrences (all)	15	22	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 November 2011	- 'Acute IPF exacerbation' was clarified each time 'exacerbation' was mentioned - Procedures and appropriate measures in case of suspicion of a 'drug induced liver injury' event were implemented - A re-test was allowed in case a laboratory parameter was found to be abnormal at Visit 1. This was to be conducted if laboratory tests were thought to be a measurement error and not related to the patient's condition - Patients were to be excluded from the trial if they were not able to follow trial procedures including completion of self administered questionnaires without help - Instructions were included for Investigators on the reporting of DLCO in the eCRF - Addition of the 'always serious AEs' according to new BI standards to ensure proper reporting of these events - Inclusion criterion 4 was changed to: 'Chest HRCT performed within 12 months of Visit 1', instead of 'Chest HRCT performed within 12 months of Visit 2'
04 September 2012	- Addition of exploratory biomarker analyses in order to explore the effect of nintedanib on biomarkers related to IPF pathology and prognostic markers of the disease. Exploratory analyses of samples from patients who gave specific informed consent were performed. Pharmacogenomic analysis was also added - The criterion for poor compliance was defined as a protocol violation

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported